Who are High dose rhCC10's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PNA, Topical pexiganan cream 0.8%, CLS001 (Omiganan), MSI-78.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/high-dose-rhcc10.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

High dose rhCC10 — Competitive Intelligence Brief

High dose rhCC10 (High dose rhCC10) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial peptide. Area: Respiratory.

phase 2 Antimicrobial peptide Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

High dose rhCC10 (High dose rhCC10) — Tufts Medical Center. High dose rhCC10 is a recombinant human tracheobronchial antimicrobial peptide that has antimicrobial properties.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
High dose rhCC10 TARGET	High dose rhCC10	Tufts Medical Center	phase 2	Antimicrobial peptide
PNA	PNA	Guangzhou Yipinhong Pharmaceutical CO.,LTD	marketed	Antimicrobial peptide	Bacterial cell membranes
Topical pexiganan cream 0.8%	Topical pexiganan cream 0.8%	Dipexium Pharmaceuticals, Inc.	phase 3	Antimicrobial peptide	Bacterial cell membrane
CLS001 (Omiganan)	CLS001 (Omiganan)	Maruho Co., Ltd.	phase 3	Antimicrobial peptide	Bacterial cell membrane (lipopolysaccharides and lipoteichoic acids)
MSI-78	MSI-78	Abeona Therapeutics, Inc	phase 3	Antimicrobial peptide	Bacterial cell membrane

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial peptide class)

Abeona Therapeutics, Inc · 1 drug in this class
Dipexium Pharmaceuticals, Inc. · 1 drug in this class
Guangzhou Yipinhong Pharmaceutical CO.,LTD · 1 drug in this class
Maruho Co., Ltd. · 1 drug in this class
Tufts Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). High dose rhCC10 — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dose-rhcc10. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab